over eight years, which could not now be repeated as an untreated control would be considered unethical. Mortality data from the trial showed a significant reduction in fatal myocardial infarction in the treatment group.' The reduction in serum cholesterol concentration observed is of a magnitude which should be advantageous.
We conclude that tamoxifen significantly reduces the serum cholesterol concentration in postmenopausal women with breast cancer. This drug, used to control one major cause of mortality in women, is found to be benefiting risk factor status for another. It may be worth exploring the potential of tamoxifen or its analogues as cholesterol lowering agents. Two errors occurred in this short report by C Harriet M Anderson and others (11 July, pp 90-1). In the first row of the table (age) the 95% confidence interval of the difference between the means should be -2 7 to 6 4 and the p value should be >0 1.
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